Back to results
US 2026/0108612 A1Published application
Beta-peptides and beta-peptide hydrogels
AssigneeMonash University
InventorsMarie-Isabel Aguilar, Mark Del Borgo, Ketav Kulkarni, Andrew Hong, John Forsythe, Bradley Broughton, Helena C. Parkington, Seyedeh Mahnaz Modarresi Saryazdi, Meg McFetridge
Life of this patent
Estimating the term…
Abstract
The present invention relates to β-peptides and hydrogels comprising the β-peptides. The hydrogels may further comprise a therapeutic cargo encapsulated within the hydrogel. Methods of preparing the hydrogels, and methods for the use of the hydrogels are also described.
Claims21
A β-peptide of formula (I):
- wherein:
- R1 is selected from —C1-20alkyl, —C2-20alkenyl, —C2-20alkynyl, —OC1-20alkyl, —OC2-20alkenyl and —OC2-20alkynyl;
- R2 is selected from —H, —OR10a, —SR10a, —N(R11a)2, —NH(C═NH)NH2, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where each cycloalkyl, aryl, heterocyclyl, and heteroaryl is unsubstituted or is substituted with one or more groups selected from —OH, —NH2, —NHC1-3alkyl, —OC1-3alkyl, —SH, —SC1-3alkyl, —CO2H, —CO2C1-3alkyl, —CONH2 and —CONHC1-3alkyl, or R2 has the following structure (A):
- R3, R4, R5, R6 and R8 are each independently selected from —H, —R9, —C1-6alkylR9, —C2-6alkenylR9 and —C2-6alkynylR9;
- or R2 and R6 together form a heterocyclic ring;
- R7 is selected from —H, —OR10a, —SR10a, —N(R11a)2, —NH(C═NH)NH2, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where each cycloalkyl, aryl, heterocyclyl, and heteroaryl is unsubstituted or is substituted with one or more groups selected from —OH, —NH2, —NHC1-3alkyl, —OC1-3alkyl, —SH, —SC1-3alkyl, —CO2H, —CO2C1-3alkyl, —CONH2 and —CONHC1-3alkyl;
- or R7 and R8 together form a heterocyclic ring;
- R9 is selected from —H, —OR10, —SR10, —N(R11)2, —C(O)R12, —NH(C═NH)NH2, cycloalkyl, aryl, heterocyclyl, and heteroaryl, where each cycloalkyl, aryl, heterocyclyl, and heteroaryl is unsubstituted or is substituted with one or more groups selected from —OH, —NH2, —NHC1-3alkyl, —OC1-3alkyl, —SH, —SC1-3alkyl, —CO2H, —CO2C1-3alkyl, —CONH2 and —CONHC1-3alkyl;
- R10 is selected from —H, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, —C(O)C1-20alkyl, —C(O)C1-20alkenyl, —C(O)C1-20alkynyl, —C(O)C1-6alkylR14, an α-peptide having 1 to 10 α-amino acid residues and an imaging agent;
- R10a is selected from —H, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, —C(O)C1-6alkyl, —C(O)C2-6alkenyl, and —C(O)C2-6alkynyl;
- each R11 is independently selected from —H, —C1-6alkyl, —C1-6alkylN(R13)2, μ-C1-6alkylNR13R14, —C2-6alkenyl, —C2-6alkynyl, —C(O)C1-20alkyl, —C(O)C1-20alkenyl, —C(O)C1-20alkynyl, —C(O)C1-6alkylR14, an α-peptide having 1 to 10 α-amino acid residues and an imaging agent;
- each R11a is independently selected from —H, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, —C(O)C1-6alkyl, —C(O)C2-6alkenyl, —C(O)C2-6alkynyl;
- R12 is selected from —OH, —OR10 and —N(R11)2;
- each R13 is independently selected from —H and —C1-6alkyl;
- R14 is an α-peptide having 1 to 10 α-amino acid residues or an imaging agent;
- or a pharmaceutically acceptable salt thereof;
- and wherein one of R1, R2, R3, R4, R8, R6 and R8 comprise a C8-20alkyl group, a C8-20alkenyl group or a C8-20alkynyl group.
14 more elements
2-32. (canceled)
Dependencies are inferred from the claim text.